10.16.26 -- How To Power Your Bioconjugation

Conjugate quality at scale depends on controlling variability from process changes, tech transfer, and site handoffs. Mixing strategy and antibody process foundations shape DAR consistency and purity.

Because conjugation creates a new molecular entity with its own stability profile, ADC formulation strategies built on mAb experience can miss critical risks, from buffer exchange-induced aggregation to photosensitivity that emerges only in the conjugated form.

Minor variability in biologics manufacturing can produce measurable differences in process performance and product quality across batches, scales, and sites. Standardized design, predictive simulation, and integrated data aim to keep tech transfer and scale-up predictable.